血小板生成素是造血生长因子家族中一个新的成员，体外培养中可明显促进巨核系造血祖细胞的增殖，体内应用后可明显升高外周血小板数及网织红细胞数。血小板生成素的问世，无疑为临床急性放射病或恶性肿瘤病人大剂量放疗、化疗后的抗出血治疗提供了广阔的应用前景 Thrombopoietin, a new member of the hematopoietic growth factor family, can significantly promote the proliferation of hematopoietic progenitor cells of megakaryocytes in vitro, and can significantly increase the number of peripheral platelets and the number of reticulocytes in vivo. The advent of thrombopoietin undoubtedly for the clinical acute radiation or malignant tumor patients with high-dose radiotherapy, anti-hemorrhage after chemotherapy provides a broad application prospects